Skip to main content
Assets
Sanofi logo
SAN.PAR
Sanofi
Health Care · Pharmaceuticals

French multinational pharmaceutical company developing vaccines, treatments for diabetes, cardiovascular diseases, oncology, and rare diseases.

HQ: FranceListed: France

Historical AI Forecasts

Audit every published iPulse AI forecast batch and immutable historical research document for Sanofi.

Historical AI Forecasts

Sanofi S.A. (SAN.PAR) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 11 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts

AI Advisor 1 AI

Independent Investor FrameworkAI Researcher

Model rating

Buy

5-Year Return Est.

+87.8%

Includes 4.17% annual net dividend contribution

1. Investment Thesis — Base Case

Sanofi presents a compelling 'growth at a reasonable price' thesis. The successful separation of the Consumer Healthcare unit (Opella) streamlines operations, allowing a re-rating as a focused biopharma entity. remains the central growth engine, with approval in COPD providing a significant revenue tailwind through 2028. While Zantac litigation is largely resolved, creating a cleaner , the market remains cautiously optimistic about the pipeline's ability to offset the eventual LOE in the early 2030s. We expect steady earnings growth, moderate , and reliable dividends to drive attractive total returns.

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in EUR.67.2684.78102.29119.81137.32Nov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in EUR.
View chart values
Historical prices and published forecast — published chart values
SeriesDateValue (EUR)
Observed price2020-11-2383.6
Observed price2020-11-2784.8
Observed price2020-12-1377.0
Observed price2020-12-2176.8
Observed price2021-01-1480.5
Observed price2021-01-1881.2
Observed price2021-02-0377.3
Observed price2021-03-0374.9
Observed price2021-03-1179.7
Observed price2021-03-1581.2
Observed price2021-04-0884.3
Observed price2021-04-2887.0
Observed price2021-05-0683.8
Observed price2021-05-2688.2
Observed price2021-06-0385.0
Observed price2021-06-0785.7
Observed price2021-06-1188.4
Observed price2021-07-1388.3
Observed price2021-07-2986.0
Observed price2021-08-0685.8
Observed price2021-08-2289.2
Observed price2021-08-3087.6
Observed price2021-09-1580.9
Observed price2021-09-2781.7
Observed price2021-10-0983.9
Observed price2021-10-2585.1
Observed price2021-11-1089.3
Observed price2021-11-2288.9
Observed price2021-11-3083.4
Observed price2021-12-2086.4
Observed price2022-01-0988.8
Observed price2022-01-2589.8
Observed price2022-01-2993.3
Observed price2022-03-0689.3
Observed price2022-03-1092.6
Observed price2022-03-1492.5
Observed price2022-04-0799.4
Observed price2022-04-11106
Observed price2022-05-0599.5
Observed price2022-05-0996.5
Observed price2022-05-25104
Observed price2022-06-06100
Observed price2022-06-1494.2
Observed price2022-07-0498.3
Observed price2022-07-12100
Observed price2022-08-0597.5
Observed price2022-08-2580.5
Observed price2022-09-1081.5
Observed price2022-09-2278.8
Observed price2022-09-2677.4
Observed price2022-10-1681.6
Observed price2022-10-2482.2
Observed price2022-11-0587.1
Observed price2022-12-0386.7
Observed price2022-12-0790.6
Observed price2022-12-1988.8
Observed price2023-01-0491.3
Observed price2023-01-1691.7
Observed price2023-02-0585.4
Observed price2023-02-1788.2
Observed price2023-03-0989.7
Observed price2023-03-1389.1
Observed price2023-04-06101
Observed price2023-04-22103
Observed price2023-04-3099.0
Observed price2023-05-24101
Observed price2023-06-0194.2
Observed price2023-06-1393.9
Observed price2023-06-2598.2
Observed price2023-07-0398.3
Observed price2023-07-1593.7
Observed price2023-08-0493.9
Observed price2023-08-2098.8
Observed price2023-09-0198.6
Observed price2023-09-21103
Observed price2023-10-11103
Observed price2023-10-1998.8
Observed price2023-10-2398.3
Observed price2023-10-2781.4
Observed price2023-11-2085.4
Observed price2023-12-1488.0
Observed price2023-12-1888.6
Observed price2024-01-1195.3
Observed price2024-01-1595.3
Observed price2024-02-0886.9
Observed price2024-02-1285.9
Observed price2024-02-2489.5
Observed price2024-03-1987.8
Observed price2024-03-2791.1
Observed price2024-04-1686.8
Observed price2024-05-0291.9
Observed price2024-05-1094.3
Observed price2024-05-3088.6
Observed price2024-06-0791.1
Observed price2024-06-1986.8
Observed price2024-07-0590.9
Observed price2024-07-2597.5
Observed price2024-08-0693.4
Observed price2024-08-2299.0
Observed price2024-08-26101
Observed price2024-09-07105
Observed price2024-10-01104
Observed price2024-10-13100
Observed price2024-10-25100
Observed price2024-11-1494.4
Observed price2024-11-2293.2
Observed price2024-12-1290.7
Observed price2024-12-1688.8
Observed price2025-01-0995.6
Observed price2025-01-1393.8
Observed price2025-02-02104
Observed price2025-02-18104
Observed price2025-03-06109
Observed price2025-03-10108
Observed price2025-04-0398.2
Observed price2025-04-1189.8
Observed price2025-05-0195.9
Observed price2025-05-0596.0
Observed price2025-05-1389.7
Observed price2025-06-0688.4
Observed price2025-06-2682.3
Observed price2025-06-3082.2
Observed price2025-07-2485.2
Observed price2025-08-0180.3
Observed price2025-08-2187.5
Observed price2025-08-2586.3
Observed price2025-09-0679.0
Observed price2025-09-2678.3
Observed price2025-10-1686.3
Observed price2025-11-0585.2
Observed price2025-11-1390.4
Observed price2025-11-1789.9
Observed price2025-12-1183.6
Observed price2025-12-1580.6
Observed price2026-01-0883.6
Observed price2026-01-1281.5
Observed price2026-01-2878.4
Observed price2026-02-0981.7
Observed price2026-02-1777.5
Observed price2026-03-1776.3
Observed price2026-04-0282.4
Observed price2026-04-1881.8
Observed price2026-04-3078.2
Observed price2026-05-0477.8
Observed price2026-05-0873.1
Observed price2026-06-0578.0
Observed price2026-06-2573.8
Observed price2026-06-2975.5
Observed price2026-07-1977.1
Observed price2026-08-0474.4
Observed price2026-08-2077.8
Observed price2026-08-2478.3
Observed price2026-09-1574.2
Observed price2026-09-1775.3
Observed price2026-09-1874.0
Published advisor forecast2025-11-2785.9
Published advisor forecast2026-05-2892.5
Published advisor forecast2026-11-2896.8
Published advisor forecast2027-05-28102
Published advisor forecast2027-11-28107
Published advisor forecast2028-05-28112
Published advisor forecast2028-11-28116
Published advisor forecast2029-05-28120
Published advisor forecast2029-11-28125
Published advisor forecast2030-05-28128
Published advisor forecast2030-11-28131

2. Scenarios & Signals

Bull case

In the bull case, Sanofi successfully transitions into a pure-play immunology and vaccine powerhouse following the Opella separation. sales exceed peak estimates, driven by COPD and pediatric indications, solidifying it as a top global drug with effectively extended exclusivity via formulation patents. The pipeline delivers high-impact blockbusters, particularly Tolebrutinib in multiple sclerosis and next-gen vaccines, silencing R&D productivity critics. Valuation multiples expand from historic discounts to match premium peers like Novartis or AstraZeneca (16x-18x P/E) as litigation risks (Zantac) fully dissipate. Robust cash flow supports aggressive dividend growth and smart .

Bear case

The bear case envisions growth plateauing earlier than expected due to intensifying competition from novel biologics and biosimilar entry preparations. Pipeline execution falters, with key late-stage assets in immunology failing to meet primary endpoints or facing regulatory delays. The US Inflation Reduction Act (IRA) aggressively targets Sanofi's top-selling drugs earlier than anticipated, compressing margins. The Opella separation fails to unlock significant shareholder value, and errors erode trust. The stock remains range-bound or declines as investors price in the looming 2031 without a proven replacement engine.

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check accessView Base planReturn to latest AI Consensus